Study Start Date
Patients may be included in the study only if they meet all of the following criteria: - Age > or = 21 years. - Histological or cytological diagnosis of malignant advanced solid tumors refractory to standard therapy or for which no suitable effective standard therapy exists. o Patients who fit above criteria will be pre-screened for presence of 1q21.3 amplification using a plasma assay based on digital PCR. Patients with tumors that exhibit 1q21.3amplification will be enrolled. Positive 1q21.3 amplification is defined as more than 3 standard deviations above the mean comparing the averaged copy number ratio of 3 genes (TUFT1, S100A8 and S100A7) relative to the reference gene RPP30 measure in sample (13). - ECOG 0-2 - Has measureable or evaluable disease based on RECIST 1.1 criteria - Estimated life expectancy of at least 12 weeks. - Has documented progressive disease from last line of therapy - Has recovered from acute toxicities from prior anti-cancer therapies - Adequate organ function including the following: - Bone marrow: - Absolute neutrophil (segmented and bands) count (ANC) > or = 1.5 x 109/L - Platelets > or = 100 x 109/L - Hemoglobin > or = 8 x 109/L - Hepatic: - Bilirubin < or = 1.5 x upper limit of normal (ULN), - ALT or AST < or = 2.5x ULN, (or < or = 5 X with liver metastases) - Renal: - Creatinine < or = 1.5x ULN - Signed informed consent from patient - Able to comply with study-related procedures. - Prior therapy (patients enrolled in phase Ib may be enrolled if they fulfil prior therapy criteria for either Cohort A or Cohort B) - Cohort A only: Has received at least 2 lines of systemic therapy (endocrine or chemotherapy) in the palliative setting. Chemotherapy in an adjuvant setting for which patients relapsed within 6 months of completion can be considered as line(s) of palliative therapy. - Cohort B only: Any number of prior lines of palliative chemotherapy.
Patients will be excluded from the study for any of the following reasons: - Treatment within the last 30 days with any investigational drug. - Concurrent administration of any other tumour therapy, including cytotoxic chemotherapy, hormonal therapy, and immunotherapy. - Major surgery within 28 days of study drug administration. - Active infection that in the opinion of the investigator would compromise the patient's ability to tolerate therapy. - Pregnancy. - Breast feeding. - Serious concomitant disorders that would compromise the safety of the patient or compromise the patient's ability to complete the study, at the discretion of the investigator. - Significant recent bleeding history defined as CTCAE grade 2 or higher within the past 3 months, unless precipitated by an inciting event (e.g. surgery, trauma, injury). - Suboptimal cardiac function, defined by: - Any history of CTCAE grade > or = 2 non-dysrhythmia cardiac conditions within the last 6 months - New York Heart Association class II, III or IV congestive cardiac failure - Left ventricular ejection fraction of <45% - QTc prolongation of >450ms as assessed by ECG or other factors that increase the risk of QT interval prolongation - Second primary malignancy that is clinically detectable at the time of consideration for study enrollment. - Symptomatic brain metastasis. - History of significant neurological or mental disorder, including seizures or dementia. - Unable to comply with study procedures - Systemic treatment with a strong CYP3A4 inhibitor or storn CYP450 inducer within 14 days prior to treatment Day 1 Phase Ib lead-in can recruit patients who fulfil critieria for either Cohort A or Cohort B AND all other inclusion/exclusion criteria